Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results , but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the ...

Biotech company 10x Genomics (NASDAQ:TXG) reported in Q4 CY2025, but sales were flat year on year at $166 million. The company expects the full year’s revenue to be around $612.5 million, close to ...

10X GENOMICS ($TXG) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.36 per share, beating estimates of -$0.48 by $0.12 ...

10x Genomics, Inc. (NASDAQ:TXG) reported a loss for the third quarter on Tuesday. The company posted a quarterly loss of 30 cents per share, compared to market expectations for a loss of 34 cents per ...

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on 10x Genomics (NASDAQ:TXG) in the last three months. The following table summarizes their recent ...

In other recent news, 10X Genomics reported its fourth-quarter 2025 earnings, outperforming expectations with an earnings per share (EPS) of -$0.13, compared to the forecasted -$0.22. The company’s ...

10x Genomics is headquartered in Pleasanton, CA. The company is focused on developing, marketing, and distributing instruments, consumables, and software for analyzing biological systems both in the ...